Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Accenture
Colorcon
Boehringer Ingelheim
Baxter
QuintilesIMS
McKesson
Daiichi Sankyo
UBS

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,226,614

« Back to Dashboard

Summary for Patent: 7,226,614
Title:Tablet comprising cetirizine and pseudoephedrine
Abstract:The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.
Inventor(s): Fanara; Domenico (Wanze, BE), Guichaux; Anthony (Fribourg, CH), Berwaer; Monique (Ham-sur-Heure-Nalinnes, BE), Deleers; Michel (Linkebeek, BE)
Assignee: UCB Farchim SA (Bulle, CH)
Application Number:11/251,895
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,226,614

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
J And J Consumer Inc ZYRTEC-D 12 HOUR cetirizine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 021150-002 Nov 9, 2007 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,226,614

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01115807Jun 28, 2001

Non-Orange Book US Patents Family Members for Patent 7,226,614

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,014,867 Tablet comprising cetirizine and pseudoephedrine ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,226,614

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I243061 ➤ Try a Free Trial
Slovakia 287645 ➤ Try a Free Trial
Slovakia 15502003 ➤ Try a Free Trial
Slovenia 1404304 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Daiichi Sankyo
Covington
Argus Health
Deloitte
US Department of Justice
Healthtrust
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.